Blog Archive
-
▼
2008
(297)
-
▼
March
(46)
- Masimo Rainbow SET Pulse CO-Oximetry Effective as ...
- Lilly : US$4.4 Million to the WHO for MDR-TB Progr...
- Nereus Pharmaceuticals : Clinical Trail of NPI-235...
- Masimo : Schiller AG Adopts its Rainbow SET as The...
- Accuray : CyberKnife Radiosurgery Used to Treat Lu...
- Actavis : approval of generic Wellbutrin SR and Zy...
- Merck Statement on the FDA Early Communication of ...
- Kamada : Advancement in its Phase II Trial with Ae...
- EpiCept, Myriad Genetics, Azixa
- Poniard Pharmaceuticals : Additional data presenta...
- AstraZeneca : Phase III Studies Of The Investigati...
- SPO Medical : Shipping PulseOx 6000(TM) and PulseO...
- MicroDose Technologies : Global License to Merck &...
- Mpex Pharmaceuticals : MP-376, Granted U.S. Orphan...
- Arriva Pharmaceuticals : Phase 2b Development of L...
- Cell Therapeutics : European Marketing Authorizati...
- Allegro Diagnostics : to Develop and Commercialize...
- AstraZeneca : Long-Term SYMBICORT® Use In Children...
- Apieron : FDA Clearance of the Insight™ eNO System...
- Genaera : MedImmune Initiation of Phase 2A Trial o...
- MAP Pharmaceuticals : Positive Results From Compar...
- GlobeImmune, Initiation of a Phase 2a Clinical Tri...
- Tongjitang to Enhance Product Portfolio with a Lea...
- AlphaMed Pharmaceuticals has successfully expresse...
- Universal Detection Technology , Anti-Microbial Pr...
- ArQule, Phase 1/2 Clinical Trial Program of ARQ 19...
- Novelos Therapeutics, Pivotal Phase 3 Lung Cancer ...
- Abbott, Genentech, Roche and OSI, Collaboration on...
- Luminex and Abbott, Agreement for Global Distribut...
- Quidel's QuickVue RSV Test : FDA Grants CLIA Waiver
- Altor BioScience , Tissue Factor Antagonists from ...
- Introgen's p53 Immunotherapy INGN 225 in Patients ...
- Inspire, Second Phase 3 Cystic Fibrosis Trial
- Expression Pathology, Research in Identifying Biom...
- Biothera’s Imprime PGG with Avastin Against Cancer
- Response Genetics, ResponseDX Tests to Select Inst...
- Gilead, Aztreonam Lysine 75 mg Powder for Nebulise...
- Alnylam, First Human Proof of Concept for an RNAi ...
- Aerocrine, NIOX MINO: a New Hand-Held Device to Me...
- KaloBios, Phase 1/2 Trial of KB002 Engineered Mono...
- Cerner and UNMHSC, agreement to evaluate dry-powde...
- Talecris Biotherapeutics, 20th Anniversary of Laun...
- Amira Pharmaceuticals and GSK, global agreement fo...
- Asthmatx, Bronchial Thermoplasty in Refractory Ast...
- Orexo, eoxins, new mechanism for asthma and COPD t...
- Boehringer Ingelheim’s BIBW 2992 for the treatment...
-
▼
March
(46)
Mar 17, 2008
Universal Detection Technology , Anti-Microbial Product Line Designed to Eliminate MRSA
February 26, 2008 - Universal Detection Technology (OTCBB: UDTT ), (Frankfurt:PO8.F ), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, commented on the recent report of a fatality caused by Methicillin-resistant Staphylococcus (MRSA) induced pneumonia of a student in Western Washington University. UDT recently launched a new hub for online sales and marketing of anti microbial products that eliminate harmful bacteria such as MRSA.
The 20 year old student was admitted to the intensive care unit at St. Joseph Hospital in Washington on February 14th after experiencing two weeks of coughing that progressed to fever, vomiting and coughing up blood. Doctors gave him antibiotics, but they were unable to help the young man, who eventually died.
Pneumonia caused by MRSA is a recent phenomenon, only being recognized as a confirmed strain 5 years ago. Adding to this growing concern is the fact that over the last number of years, the MRSA bug has been moving out of nursing home and hospital settings and into public places such as schools. This is the second reported death of a student from MRSA in the last year. MRSA is responsible for more than 94,000 serious infections and nearly 19,000 deaths each year... Universal Detection Technology's Press Release -